Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
On Sept. 16 Novo Nordisk (NYSE: NVO) and Korro Bio (NASDAQ: KRRO) announced that they'd be starting a new drug-development collaboration worth hundreds of millions of dollars, in an area that most ...
Novo Nordisk’s American depositary receipts tumbled almost 6% Friday after the drugmaker reported mixed results from a study of an experimental weight-loss pill. The pill, monlunabant, helped people ...
Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...
Under terms of the deal, Novo Nordisk will get an exclusive license to use NanoVation’s lipid nanoparticle technology for two lead programs, and NanoVation will receive up to US$600 million in ...
(RTTNews) - Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Wegovy ...
Novo Nordisk's weight-loss drugs, Ozempic and Wegovy, have multiple positive catalysts, making NVO stock attractive for medium-to-long term investors. Insurance coverage for Ozempic and Wegovy may ...
Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program ...
Ahead of a Senate hearing next week at which Novo Nordisk’s CEO has been called to testify, health committee chair Bernie Sanders is keeping the heat on the company. Since April of this year ...
In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve more than 13% weight loss, but that has been over much longer time ...
Sept 17 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback